
Thoracic Medical Oncologist, Assistant Professor @MayoClinic AZ ☀️ Specializing in solid tumor cellular therapies, phase 1 trials, lung cancer 🫁 Views my own
Mayo Clinic
Joined March 2019
- Tweets522
- Following645
- Followers1.1K
- Likes1.8K
Pinned Tweet
It’s not official till the X bio is updated! Excited to join the wonderful team at @MayoClinic Arizona! @MayoCancerCare
Antonious Z. Hazim, MD retweeted
FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class?
fda.gov/drugs/cancer-approva…
Antonious Z. Hazim, MD retweeted
Neladalkib (ALK inhibitor) now @US_FDA ✅ for TKI-pretreated ALK+ mNSCLC off #ALKOVE1:
- ORR 46% in Lorlatinib-naïve & 26% post-Lorlatinib. ORR 49% post-Alectinib
- DOR ≥12mos: 80% & 54%
- mDOR NR & 17.6mos
- Common AEs: ⬆️ LFTs and peripheral edema
#lcsm #OncTwitter
🚨🔥@OncoAlert Hot off the press.
‼️#BigNews
@FDA just #APPROVED a NEW #ALK inhibitor:
⭐️⭐️#Neladalkib
Approval for:
❇️# Patients with Advanced #ALK+ non-small cell #LungCancer (#NSCLC) who have previously received the following therapy:
🔹One prior ALK #TKI consisting of alectinib
OR
🔹Two or more prior ALK #TKIs & #Chemotherapy.
👇🏻
fda.gov/drugs/cancer-approva…
Antonious Z. Hazim, MD retweeted
Proud to support Dr. Rami Manochakian (@RamiManochakian) in the @ASCO Election! The best PD & mentor! An amazing human, friend & fantastic leader invested in patient care, trainee education, and moving oncology forward!
Cast your vote today! 🗳️🩺 #ASCO
#Voting for @ASCO Election is now open.
I am #honored & #humbled to be running as one of the candidates, for the #ASCO #NominatingCommittee, alongside many remarkable talented candidates & GREAT colleagues.
Visit asco.org/election to learn more about the candidates & place your vote!
Antonious Z. Hazim, MD retweeted
🔥🚨#November is 🫁
#LungCancerAwareness Month.
⭐️Lung Cancer Awareness #SavesLives.
✅Together, WITH #Patients, we keep the #Fight against #LungCancer.
✅We have made a great #Progress but still have a long way to go. #LCAM26.
👇🏼Sharing, like every year, my:
‼️#AWARENESS #Mnemonic
🤖 Made with AI
Antonious Z. Hazim, MD retweeted
🚨🔥@OncoAlert Hot off the press.
Just published @NEJM in conjunction with presentation @myESMO #ESMO26
the long-awaited #PracticeChanging results of:
⭐️#DeLLphi305 phase 3 trial of:
❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab.
Study showed:
‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit.
✅#mOS: 21.1 vs 12.7 months (HR 0.42)
✅12-month OS: 79.4% vs 53.3%
✅#mPFS: 7.4 vs 1.9 months (HR 0.34)
⚠️ Grade ≥3 #AEs: 46.8% vs 40.6%
* In Tarlatamab arm:
#CRS: 49.6% (Grade ≥3: 0.4%)
#ICANS: 1.1% (Grade ≥3: 0%)
👇🏻
nejm.org/doi/full/10.1056/NE…
Antonious Z. Hazim, MD retweeted
Pope Leo XIV has been diagnosed with lung adenocarcinoma.
While we had hoped for a different diagnosis, the fact that he was able to undergo a lobectomy is encouraging. Surgery is generally pursued when lung cancer appears localized and potentially curable.
Final pathology will help determine prognosis and whether additional treatment is needed.
Wishing the Holy Father a smooth and speedy recovery.
lombardi.georgetown.edu/lomb…
Antonious Z. Hazim, MD retweeted
Human! Know thyself!
Pick any medical specialty other than your own. Who’s the most famous physician in it? You probably can’t name one.
Almost none of us will be known outside our field, and even those who achieve real professional fame are mostly forgotten within a few decades.
Fame is a poor reason to devote your life to medicine. The work itself matters more: caring for patients, discovering new knowledge, and teaching the next generation.
Antonious Z. Hazim, MD retweeted
🔥IDeate-Lung01: "Data do not satisfy requirements needed to support an accelerated approval — BLA voluntarily withdrawn"
🆙 @DaiichiSankyoUS @Merck
👥Patients: Extensive-stage small cell lung cancer (ES-SCLC), progressed on/after platinum-based chemotherapy
2⃣Phase II
⚖️Ifinatamab deruxtecan (I-DXd)
🔢NCT05280470
#LCSM @OncoAlert @Larvol @IASLC
🔗 daiichisankyo.us/press-relea…
☑️#WCLC25 #LCSM Oral🆙
🔥Ifinatamab Deruxtecan (I-DXd, B7-H3 ADC)
🔥I-DXd in ES-SCLC: Primary Analysis of the Phase 2 IDeate-Lung01 Study
🎯 ORR 2L/3L+: 56.3%/45.7%
🎙️ Dr. Myung-Ju Ahn
@OncoAlert @Larvol @OncLive @IASLC
cattendee.abstractsonline.co…
Antonious Z. Hazim, MD retweeted
Sharing our recent manuscript highlighting DLL3 IHC predictive of tarlatamab response and long-term outcome, check this out!
Key findings:
1. DLL3 IHC expression in patient tissue ranging widely from 0% to 100% (median of 70% and 75%, in two datasets)
2. DLL3 expression above 75% experienced a significantly longer median time on tarlatamab (ToT)treatment (10.1 months vs. 2.9 months) compared to those with ≤75% expression.
3. Patients achieving a PR to tarlatamab had a higher median DLL3 expression level (80%) than those with PD (40%)
biorxiv.org/content/10.64898… @LaurenByersMD @LauraAlderMD @lungoncdoc @drshieldsmd @kyleconcannonMD @SclcSMASHERS k
Antonious Z. Hazim, MD retweeted
A positive ctDNA result does not necessarily mean MRD.
In NSCLC surveillance, 59% of patients with a positive methylation-based ctDNA result subsequently became negative, mostly without radiologic recurrence. Low-level signals around the assay’s detection limit were particularly unstable. In contrast, all three patients with clearly higher ctDNA fractions had confirmed recurrence.
As ctDNA increasingly enters perioperative trials and potentially treatment decisions, perhaps the clinically relevant biomarker is not simply ctDNA+/−, but its level, persistence, and trajectory.
A single low-level positive result may be a poor reason to label a patient as having molecular residual disease and escalate treatment. This is a small retrospective study, but an important warning against reducing MRD to a binary variable.
I raised a similar concern when discussing SERENA-6. Unfortunately, it did not attract the editor’s interest at the time and was therefore not published in a “scientific journal.” Given the sometimes difficult-to-understand discretionary nature of editorial decisions, I have increasingly chosen to share some of my scientific views independently, as I did in the post below.
jtocrr.org/article/S2666-364…
Thoughts on SERENA-6 is a personal commentary that has not been published in conventional academic journals.
From now on, I will share my personal writings in this format as a protest against a publishing system shaped by arbitrary editorial decisions, editors’ personal biases and conflicts of interest, favoritism within professional networks, excessive article processing charges, and the coercive “publish or perish” culture.
Antonious Z. Hazim, MD retweeted
Nice slides to see cross trial comparisons in EGFR exon 20 insertion space .
By Dr Bazhenova @StephenVLiu @IASLC @RManochakian @OncBrothers
Antonious Z. Hazim, MD retweeted
🚨🔥@OncoAlert Hot off the press.
Just published @NEJM
⭐️Results of phase 1/2 trial of:
#Daraxonrasib (the famous & just approved drug in pancreas cancer) in:
✅Previously Treated #RAS-Mutant Non–Small-Cell #LungCancer (#NSCLC).
❇️#ORR:
31% at dose of 120 mg or less)
34% at doses of 160-220 mg)
37% at dose of 300 mg (the approved dose for pancreas cancer).
❇️#AEs ( ≥ grade 3): 54%
👇🏻
nejm.org/doi/full/10.1056/NE…
Antonious Z. Hazim, MD retweeted
🔥🚨 @OncoAlert Hot off the press.
Just published @Annals_Oncology
⭐️Five-Year Outcomes of #Keynote671
trial of #Perioperative #Pembrolizumab + chemo vs chemo alone in resectable stage II-IIIB non-small cell #LungCancer (#NSCLC).
✅⬆️5-year #EFS
49.9% (pembro arm) vs 26.5% (HR, 0.58)
✅⬆️5-year #OS
64.6% (pembro arm) vs 53.6% (HR, 0.74)
👇🏻
annalsofoncology.org/article…
Antonious Z. Hazim, MD retweeted
🆙#WCLC26 #LCSM Plenary Session
🔥PAPILLON: First-Line Amivantamab-Chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall Survival
🎙️ @chulkimMD
🔢PL03.03
☑️NCT04538664
🔗 cattendee.abstractsonline.co…
@OncoAlert @Larvol @IASLC @EGFRResisters @Exon20Group
🔥PAPILLON🦋: Amivantamab+Chemo (Cx) vs. Cx
🎙️@nicogirardcurie
🎯PFS HR 0.40 (95%CI 0.30-0.53). OS HR 0.67 (0.42-1.06). Ami+Cx/Cx: ORR 73/47%, median PFS 11.4/6.7mo.
✅Phase III RCT
✅Primary: PFS
✅1st line EGFR Exon20ins mNSCLC
✅NCT04538664
#ESMO23 #LCSM @myESMO @OncoAlert
Antonious Z. Hazim, MD retweeted
What’s your queue #? My highest is 50k. Lowest 5k.
Get ready! D23 exclusives drop online tomorrow at 8AM PT! You can preview all items now. There will most likely be a queue for the drop.
.
distracker.info/4g1iFJ9
.
#Ad #Disney #DisneyStore #Collectibles #DisneyPins #Marvel #StarWars
Antonious Z. Hazim, MD retweeted
🎯 First line T-DXd improved PFS over the platinum-pemetrexed-pembro triplet in HER2m NSCLC daiichisankyo.us/web/dsi/pre…
Antonious Z. Hazim, MD retweeted
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.
Read the full article. bit.ly/3UbxfoH
#NSCLC






























































